Qomel Company Limited (9600) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Qomel Company Limited SAR 49.61, price SAR 36.00, upside +37.8%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Qomel Company Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
29‑month range 36.00 SAR – 67.50 SAR · fair‑value band 36.58 SAR – 62.64 SAR · the 36.00 SAR price screens below the 49.61 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Qomel Company in your weekly email
Every Wednesday you see whether Qomel Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Qomel Company Limited operates as a healthcare company in Saudi Arabia. The company is involved in the sale of medicine and natural medicinal herbs. It also offers pharmaceutical and medical supplies services. The company was founded in 2007 and is headquartered in Riyadh, Saudi Arabia.
Stock analysis
Qomel Company Limited (9600) currently trades at 36.00 SAR, while our model-based Fair Value estimate is 49.61 SAR, implying the stock looks roughly 27.4% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 61.65 SAR per share, and 10 of the 14 models we run sit above the 36.00 SAR price.
Bear case: the Asset-Based group reads lowest at 11.47 SAR, and 4 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 36.58 SAR (bear) to 62.64 SAR (bull), the price of 36.00 SAR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Qomel Company Limited reported revenue of 132M SAR in FY2025 versus 61.2M SAR in FY2021, a compound +21.2%/yr. Reported net income was 15.0M SAR in FY2025, compounding +25.0%/yr from FY2021.
Key figures
Market cap 336M SAR (≈ $89.5M) · P/E ratio 16.8 · P/S ratio 1.90 · EPS (TTM) 2.14 SAR · Net margin 11.3% · Return on equity 13.3% · Return on assets (EBIT) 16.6% · Operating margin 9.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 38%, 9600 screens cheaper than that median.
Fair Value models
Bear 36.58 SARFair Value 49.61 SARBull 62.64 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.61 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+3.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside+37.8% · Above median
Profitability
Return on equity (TTM)13.3% · Top 25%
Return on assets6.2% · Top 25%
Net margin (TTM)11.3% · Top 25%
Operating margin (TTM)9.6% · Top 25%
Growth and dividend
Revenue growth−7.1% · Bottom 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Qomel Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/9600
Frequently asked questions
Is Qomel Company Limited (9600) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 49.61 SAR versus a price of 36.00 SAR, about +38% upside (undervalued).
What is the fair value of 9600?
Our model-based fair value for Qomel Company Limited is 49.61 SAR (as of Sep 27, 2026), built from audited fundamentals. The current price: 36.00 SAR.
What is the quality score of 9600?
Qomel Company Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qomel Company Limited (9600)?
Our model-based price target is the fair value of 49.61 SAR (as of Sep 27, 2026) from 14 valuation models. Cautious scenario 36.58 SAR, optimistic scenario 62.64 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Qomel Company Limited stock forecast for 2026?
Our models put fair value at 49.61 SAR, about +38% upside versus a price of 36.00 SAR (undervalued). Cautious scenario 36.58 SAR, optimistic scenario 62.64 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Qomel Company Limited (9600)?
Qomel Company Limited reported trailing-twelve-month revenue of about 132M SAR (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Qomel Company Limited (9600)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qomel Company Limited it is 49.61 SAR per share (as of Sep 27, 2026), against a price of 36.00 SAR. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Qomel Company Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 9600 trades below its calculated fair value: price 36.00 SAR, fair value 49.61 SAR, a gap of about +38% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9600?
No. The price is what the market pays today (36.00 SAR); the fair value is what the company's own numbers justify (49.61 SAR). For Qomel Company Limited the two are 13.61 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Qomel Company Limited worth?
The market values Qomel Company Limited at about 336M SAR (market capitalisation, as of Sep 27, 2026). Per share that is 36.00 SAR; our models calculate a fair value of 49.61 SAR per share.
What do the bullish and bearish scenarios say about 9600?
Our models span a range for Qomel Company Limited: cautious scenario 36.58 SAR, base 49.61 SAR, optimistic 62.64 SAR per share (as of Sep 27, 2026, price 36.00 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9600?
Qomel Company Limited trades at a price-to-earnings ratio of 16.8 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 49.61 SAR is built from several models across several years. Other multiples: P/B 2.8, P/S 2.5, EV/EBITDA 16.8.
How solid is the balance sheet of Qomel Company Limited (9600)?
Balance-sheet figures for Qomel Company Limited (as of Sep 27, 2026): return on equity 13.3%, debt of 0.19 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is 9600 from its 52-week high?
Qomel Company Limited trades at 36.00 SAR, about 39% below its 52-week high of 59.25 SAR and at the low of 36.00 SAR (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 49.61 SAR is for.
Which stocks are comparable to Qomel Company Limited?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qomel Company Limited stock attractive at the current price?
The data as of Sep 27, 2026: price 36.00 SAR, calculated fair value 49.61 SAR (+38%), Quality Score 28/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9600 calculated?
We run Qomel Company Limited through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 49.61 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Qomel Company Limited currently trades 27 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qomel Company Limited (9600)?
The closing price on Sep 30, 2026 was 36.00 SAR. Our model-based fair value is 49.61 SAR, about +38% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qomel Company Limited right now?
The large discount to fair value meets weak quality (28/100). That raises the risk this is a value trap rather than a bargain. The price sits below our cautious bear case: the market assumes less than even our pessimistic scenario. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Qomel Company Limited
How large is the market capitalisation of Qomel Company Limited (9600)?
The market capitalisation of Qomel Company Limited is 336M SAR (≈ $89.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qomel Company Limited (9600)?
The price-to-sales ratio of Qomel Company Limited is 1.90 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qomel Company Limited (9600)?
Earnings per share at Qomel Company Limited are 2.14 SAR (price ÷ EPS = P/E 16.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Qomel Company Limited (9600)?
The net margin of Qomel Company Limited is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qomel Company Limited (9600)?
The return on equity (ROE) of Qomel Company Limited is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qomel Company Limited (9600)?
On an EBIT basis the return on assets of Qomel Company Limited is 16.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qomel Company Limited (9600)?
The operating margin of Qomel Company Limited is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qomel Company Limited (9600)?
Revenue at Qomel Company Limited is growing −7.1% versus a year earlier (3y avg +19.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qomel Company Limited (9600)?
Earnings per share at Qomel Company Limited are growing −37.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Qomel Company Limited (9600) generate?
The free cash flow of Qomel Company Limited is −25.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Qomel Company Limited (9600) carry?
The net debt of Qomel Company Limited is 17.7M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Qomel Company Limited in the live analysis
One click puts Qomel Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
